Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Hemophilia A – Unmet Need – Unmet Need – Severe Hemophilia A Without Inhibitors (US/EU)
The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments…
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (Dashboard) (US)
Immune thrombocytopenic purpura (ITP) has a complex treatment algorithm comprising many therapies, different combinations of which serve as first-, second-, and later-line treatments. Key…
Immune Thrombocytopenic Purpura | Treatment Algorithms: Claims Data Analysis | US | 2020
Immune thrombocytopenic purpura (ITP) has a complex treatment algorithm comprising many therapies, different combinations of which serve as first-, second-, and later-line treatments. Key…
Myelodysplastic Syndromes – Access & Reimbursement – Access & Reimbursement – Myelodysplastic Syndromes (US)
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias. Based on our survey results, the U.S. reimbursement environment…
Myelodysplastic Syndromes – Current Treatment – Current Treatment: Physician Insights – Myelodysplastic Syndromes (US)
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia. Treatment goals…
